ALK and non-small cell lung carcinoma: An international multicenter real-world study analyzed data from 76 ALK-positive NSCLC patients treated with second-line or later lorlatinib, including 52 patients with brain metastasis.In that study, the intracranial ORR was 35%, and the DCR was 87% (25).